$AMRN News
Last published 2d ago
- 2d agoAMRNAmarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026GlobeNewswireDUBLIN and BRIDGEWATER, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted new clinical
- 2w agoAMRNAmarin Corporation Third Quarter 2026 Results - AMARIN CORP PLCEarnings Call TranscriptsGreetings, and welcome to the Ameren Corporation's 3rd Quarter 2026 Results Conference Call. At this time, all participants are on a listen-only mode, and a question-and-answer session will follow the formal presentation
- 2w agoAMRNAMARIN CORP PLC\UK - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoAMRNAmarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net IncomeGlobeNewswireDUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results
- 2w agoAMRNAmarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)GlobeNewswirePre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With
- 3w agoAMRNAmarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026GlobeNewswireDUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third
- 2mo agoAMRNAmarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026GlobeNewswirePresentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA)
- 2mo agoAMRNNew REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent PatientsGlobeNewswireDUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc
- 2mo agoAMRNNew Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026GlobeNewswireDUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming
- 3mo agoAMRNAmarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market PresenceGlobeNewswireQ2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market
- 3mo agoAMRNAmarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026GlobeNewswireDUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will
- 4mo agoAMRNAmarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment LandscapeGlobeNewswireDUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA
- 5mo agoAMRNNew REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with HypertriglyceridemiaGlobeNewswireDUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new
- 6mo agoAMRNAmarin Corporation First Quarter 2026 Results - Amarin CorporationEarnings Call TranscriptsGood day ladies and gentlemen and welcome to the Ameren Corporation's first quarter 2026 results conference call. At this time all participants are in a listen-only mode and a question and answer session will follow the
- 6mo agoAMRNAmarin Reports 2026 First Quarter Financial ResultsGlobeNewswireTotal Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Medical Society
- 7mo agoAMRNAmarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026GlobeNewswireDUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first
- 7mo agoAMRNAmerican College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk ReductionGlobeNewswireDUBLIN and BRIDGEWATER, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today
- 8mo agoAMRNNew REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoGlobeNewswireDUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that
- 8mo agoAMRNEffects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive CardiologyGlobeNewswirePeer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on
- 8mo agoAMRNAmarin Corporation Fourth Quarter 2025 Results - Amarin CorporationEarnings Call TranscriptsWelcome to Ameren Corporation's conference call to discuss its fourth quarter 2025 financial results. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal present
- 8mo agoAMRNAmarin Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireStrategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market
- 8mo agoAMRNThis American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular DiseaseGlobeNewswireDUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to
- 9mo agoAMRNAmarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026GlobeNewswireDUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth
- 10mo agoAMRNAmarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category CommercializationGlobeNewswireDUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in
- 10mo agoAMRNAmarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth OpportunitiesGlobeNewswireDUBLIN and BRIDGEWATER, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select preliminary
- 1y agoAMRNNew REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk PatientsGlobeNewswireDUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of
- 1y agoAMRNAmarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025GlobeNewswireDUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new
- 1y agoAMRNAmarin Reports Third Quarter 2025 Financial ResultsGlobeNewswireCompany completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand,
- 1y agoAMRNAmarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular BenefitGlobeNewswireDUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement
- 1y agoAMRNAmarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025GlobeNewswireDUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report
- 1y agoAMRNAmarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular CongressGlobeNewswireDUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian
- 1y agoAMRNAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025GlobeNewswireDUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)] oxidation and on
- 1y agoAMRNNew REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient SubgroupsGlobeNewswire-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRIDGEWATER, N.J., Aug.
- 1y agoAMRNNew Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025GlobeNewswireDUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August
- 1y agoAMRNAmarin Corporation plc (AMRN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAMRNAmarin Reports Second Quarter 2025 Financial ResultsGlobeNewswire-- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2
- 1y agoAMRNAmarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025GlobeNewswireDUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's
- 1y agoAMRNAmarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in EuropeGlobeNewswire-- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.m. EDT with
- 1y agoAMRNAmarin Reports First Quarter 2025 Financial ResultsGlobeNewswire-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of
- 1y agoAMRNAmarin Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025
- 1y agoAMRNAmarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025GlobeNewswireDUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's
- 1y agoAMRNAmarin Confirms Effective Date for 1-For-20 ADS Ratio ChangeGlobeNewswireDUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today confirmed that April 11, 2025 will be the effective date for the Company's previously announced Ratio Change
- 1y agoAMRNAmarin Appoints JEC Capital Partners' Michael Torok to Board of DirectorsGlobeNewswireDUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC
- 1y agoAMRNAmarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 AgonistGlobeNewswireDUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid
- 1y agoAMRNConcerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of UnderperformanceBusiness WireBradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with certain of their affiliates, the "Concerned Shareholder Group" or "we"), who collectively own approximately 15 million
- 1y agoAMRNNew Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoGlobeNewswireDUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the
- 1y agoAMRNAmarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) ProgramGlobeNewswireDUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced its intent to effect a ratio change on its American Depositary Shares ("ADS") from one (1) ADS
- 1y agoAMRNAmarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate ActionGlobeNewswire-- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million -- -- Fourth Quarter and Full-Year 2024 Performance Reflects
- 1y agoAMRNAmarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol LoweringGlobeNewswire-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Very Well-Controlled
- 1y agoAMRNAmarin Receives National Reimbursement for VAZKEPA® in AustriaGlobeNewswire-- Austrian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Risk of Cardiovascular Events in Eligible Patients -- -- Effective 1 April 2025, Austrian Reimbursement